| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 3.6MM | +3% |
| Gross Profit | 132K | -78% |
| Cost Of Revenue | 3.5MM | +20% |
| Operating Income | -14.2MM | -9% |
| Operating Expenses | 14.3MM | -11% |
| Net Income | -14.3MM | -9% |
| R&D | 4.2MM | -26% |
| G&A | 5.5MM | +34% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens.
DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.
DarioHealth Corp. (NASDAQ:DRIO) Q4 2023 Earnings Call Transcript March 28, 2024 DarioHealth Corp. beats earnings expectations. Reported EPS is $-0.41, expectations were $-0.54. DRIO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the DarioHealth Fourth Quarter […]
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
In this article, we will be taking a look at the 11 best small cap AI stocks to buy now. To skip our detailed analysis of the AI sector, you can go directly to see the 5 Best Small Cap AI Stocks To Buy Now. AI: A Consequential Technology Artificial intelligence has taken the world […]
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 4th quarter ended December 31, 2023, on Thursday, March 28th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time.
DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy.
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital health market, today announced that management will participate in the Cowen 44th Annual Healthcare Conference, which is being held March 4-6, 2024, at the Boston Marriott Copley Place in Boston, Massachusetts.
The deal, which Dario says will boost revenue and speed profitability, comes as the digital health sector could see increased M&A activity this year.